Photo of Anne-Marie A. Wills, MD, MPH

Anne-Marie A. Wills, MD, MPH

617-726-5532

Accepting New Patients

Overview

To make a clinic appointment, please call 617-726-5532

For research questions, please call 617-726-4936

Departments

Neurology

Clinical Interests
  • Movement disorders
  • Progressive supranuclear palsy (PSP)
  • Parkinson's disease
  • Amyotrophic lateral sclerosis (ALS)
Medical Education
  • MD, Columbia University College of Physicians and Surgeons
  • MPH, Harvard School of Public Health
  • Residency, Brigham and Women's Hospital
  • Fellowship, Massachusetts General Hospital
Board Certifications
  • Neurology
Foreign Languages
  • Spanish
Locations
  • Boston: Massachusetts General Hospital
Existing Patients
Patient Gateway
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • BMC HealthNet Mass Health MCO/ACO
  • Cigna (PAL #'s)
  • Commonwealth Care Alliance
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • MassHealth
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Connecticut
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • OSW - Vermont
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
  • Well Sense Pediatrics

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.

Patient Age Group
Adult
Provider Gender
Female

Biography

Anne-Marie Wills MD MPH is a Neurologist specializing in neurodegenerative disease, such as Parkinson's Disease, PSP, and ALS. She received her BA from Princeton University, her MD from Columbia College Physicians & Surgeons, and her MPH from Harvard School of Public Health. She completed her specialty training in the Partners Neurology residency program, a combined program between Massachusetts General Hospital and Brigham and Women's Hospital. She has been on staff at M.G.H. since 2006.

Dr. Wills' research focuses on environmental risk factors and determinants of neurodegenerative disease progression, including nutrition, caffeine and pesticides. Her multi-center clinical trial of nutrition in ALS (funded by the Muscular Dystrophy Association) showed that a calorically-dense diet was better tolerated and led to fewer adverse events, including deaths, than a standard diet (Wills et al. The Lancet, 2014).  She is also investigating the effects of exercise interventions for neurodegenerative diseases.

She is the director of the CurePSP Center of Care at MGH which provides multidisciplinary care for people with Progressive Supranuclear Palsy.  She is a member of the Movement Disorders Society, the Parkinson’s Study Group (PSG), the NorthEast ALS Consortium, and the American Academy of Neurology.  She is co-director of the Genes and Environment Working Group of the PSG, co-founder of the Atypical Parkinsonian Disorders working group of the PSG and is the PI of several clinical trials in Parkinson’s disease and PSP.

Research & Publications

Research Summary

Dr. Wills' research focuses on environmental risk factors and determinants of neurodegenerative disease progression, including nutrition, caffeine and pesticides. Her multi-center clinical trial of nutrition in ALS (funded by the Muscular Dystrophy Association) showed that a calorically-dense diet was better tolerated and led to fewer adverse events, including deaths, than a standard diet (Wills et al. The Lancet, 2014).  She has shown that weight loss is associated with worse disease progression in Parkinson's disease (Wills et al. JAMA Neurology, 2016).  She is also the Principal Investigator of several Parkinson's Disease clinical trials testing exercise interventions in PD and the director of the MGH CurePSP Center of Care for Progressive Supranuclear Palsy.

Publications

View my most recent publications at PubMed

Paganoni S; Deng J; Jaffa M; Cudkowicz ME; Wills AM. Body Mass Index, not dyslipidemia, is an independent predictor of survival in ALS. Muscle and Nerve. 2011 44(1):20-4

Paganoni S; Zhang M; Quiroz Zárate A; Jaffa M; Yu H; Cudkowicz ME; Wills AM. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. Journal of Neurology. 2012 259 (9):1923-1928.

Wills AM, Eberly S, Tennis M, et al. Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord. 2013

Wills AM, Hubbard J, Mackline EA et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial, The Lancet, Online Publication, 28 February 2014

Wills AM, Pérez A, et. Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease. JAMA Neurol. 2016 Mar;73(3):321-8.

 

 

News & Events

  • Early weight loss in Parkinson disease patients may signify more serious form of disease

    While weight loss is common in Parkinson’s patients, results of a study led by an MGH investigator could suggest that weight loss early in the course of the disease signifies a more serious form of the neurodegenerative disorder.

  • High-calorie feeding may slow progression of ALS

    Increasing the number of calories consumed by patients with amyotrophic lateral sclerosis (ALS) may be a relatively simple way of extending their survival. A phase 2 clinical trial led by Massachusetts General Hospital physicians found that ALS patients receiving a high-calorie, high-carbohydrate tube-feeding formula lived longer with fewer adverse events than participants who received a standard formula designed maintain their weight.

  • Mild obesity appears to improve survival in ALS patients

    Patients with amyotrophic lateral sclerosis (ALS) may be an exception to the rule that being overweight is a health hazard. In a retrospective study of over 400 ALS patients, MGH researchers found that those who were mildly obese survived longer than patients who were normal weight, underweight or even overweight.

Contact

Neurology & Stroke Services
15 Parkman Street
Boston, MA 02114-3117
Phone 1: 617-726-5532
Phone 2: 617-724-9234
Fax: 617-726-4101

Back to Top